33 related articles for article (PubMed ID: 7392707)
1. Immunological adverse effects of anticonvulsants. What is their clinical relevance?
De Ponti F; Lecchini S; Cosentino M; Castelletti CM; Malesci A; Frigo GM
Drug Saf; 1993 Mar; 8(3):235-50. PubMed ID: 8452664
[TBL] [Abstract][Full Text] [Related]
2. Hydantoin-induced cutaneous pseudolymphoma with clinical, pathologic, and immunologic aspects of Sézary syndrome.
D'Incan M; Souteyrand P; Bignon YJ; Fonck Y; Roger H
Arch Dermatol; 1992 Oct; 128(10):1371-4. PubMed ID: 1417026
[TBL] [Abstract][Full Text] [Related]
3. [Malignant lymphoma following years of hydantoin treatment for epilepsy].
Jungi WF; Senn HJ; Stanisic M; Rösli R
Schweiz Med Wochenschr; 1975 Dec; 105(50):1735-7. PubMed ID: 1215968
[TBL] [Abstract][Full Text] [Related]
4. Hodgkin's and non-Hodgkin's lymphomas masquerading as "idiopathic" liver granulomas.
Aderka D; Kraus M; Avidor I; Sidi Y; Weinberger A; Pinkhas J
Am J Gastroenterol; 1984 Aug; 79(8):642-4. PubMed ID: 6465111
[TBL] [Abstract][Full Text] [Related]
5. Malignant lymphoma in western Ethiopia.
Getachew A
East Afr Med J; 2001 Aug; 78(8):402-4. PubMed ID: 11921560
[TBL] [Abstract][Full Text] [Related]
6. Dendritic reticulum cell immunoreactivity for low-affinity nerve growth factor receptor in malignant lymphomas.
Dorfman DM; Shahsafaei A
Mod Pathol; 1996 Oct; 9(10):959-65. PubMed ID: 8902831
[TBL] [Abstract][Full Text] [Related]
7. [Hodgkin's disease following treatment with hydantoins. Report of a case and review of the literature (author's transl)].
Bladé Creixenti J; Segura Porta F; Nogué Xarau S; Soriano Marín E; García San Miguel J
Med Clin (Barc); 1980 Jun; 75(1):24-6. PubMed ID: 7392707
[TBL] [Abstract][Full Text] [Related]
8. Demonstration of composite nodal B-cell lymphoma and subsequent Hodgkin's disease by flow cytometry and immunohistochemistry. Case report and review of the literature.
Dunphy CH; Craver JL; Emerson WA
Arch Pathol Lab Med; 1997 Jun; 121(6):637-40. PubMed ID: 9199634
[TBL] [Abstract][Full Text] [Related]
9. Hodgkin's disease following non-Hodgkin's lymphoma. A clinicopathologic and immunophenotypic study of nine cases.
Zarate-Osorno A; Medeiros LJ; Kingma DW; Longo DL; Jaffe ES
Am J Surg Pathol; 1993 Feb; 17(2):123-32. PubMed ID: 8422110
[TBL] [Abstract][Full Text] [Related]
10. Coexistence of Hodgkin's disease and giant lymph node hyperplasia of the plasma-cell type (Castleman's disease).
Abdel-Reheim FA; Koss W; Rappaport ES; Arber DA
Arch Pathol Lab Med; 1996 Jan; 120(1):91-6. PubMed ID: 8554455
[TBL] [Abstract][Full Text] [Related]
11. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
12. [Classification of malignant lymphomas].
Murohashi I
Rinsho Byori; 2001 Mar; Suppl 115():54-63. PubMed ID: 11391937
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
